We have previously reported on cloning of the human gene encoding Bcl-2/adenovirus E1B 19 kDa-interacting protein 3-like protein (Bnip3L) and its growth inhibitory eect on cancer cells. Here we show that Bnip3L contains a motif similar to the BH3 domain which is conserved in Bcl-2 family proteins as well as containing a membrane-anchoring domain, and that Bnip3L interacts with Bcl-2 and Bcl-x L . Immuno¯uorescence microscopy revealed that Bnip3L was localized in the mitochondria, when in the presence of the membrane-anchoring domain. Transient expression of Bnip3L induced apoptosis of Rat-1 and HeLa cells and mutational analysis revealed that the BH3 domain and the membrane-anchoring domain were required for Bnip3L to induce cell death. Addition of recombinant Bnip3L to isolated mitochondria induced membrane potential loss and cytochrome c release both of which have been suggested to be prerequisite for apoptotic cell death. These results suggest that Bnip3L is one of the BH3-containing proapoptotic proteins and that it targets the mitochondria when inducing apoptosis.
Introduction
Apoptosis is an essential physiological process for the selective elimination of cells, and its dysregulation contributes to a variety of diseases, including cancer, autoimmunity, and neurodegenerative disorders (reviewed by Thompson, 1995) . In virus-infected cells, apoptotic paradigms are initiated as a cellular defense mechanism, and some viruses encode anti-apoptotic proteins to suppress the apoptosis of infected permissive cells and thereby allow the virus to multiply. One of the proteins encoded by adenovirus, E1B 19 kDa protein, is a functional homologue of anti-apoptotic Bcl-2 that eciently inhibits apoptosis induced by various other stimuli (reviewed by Adams and Cory, 1998) .
Bnip3 was identi®ed as an E1B 19 kDa-interacting protein using a yeast two-hybrid system, and was also shown to bind to Bcl-2 and to be localized in the mitochondria (Boyd et al., 1994) . Bnip3 has recently been shown to possess the BH (Bcl-2 homology) 3 domain, which is a short stretch of sequences shared by all Bcl-2 family proteins (both the anti-apoptotic and pro-apoptotic members). The pro-apoptotic Bcl-2 subfamily includes proteins which share sequence homology only at the BH3 region, so-called BH3-proteins such as Bik, Bid and Bim, as well as proteins with homology at BH1, BH2 and BH3, like Bax and Bak. Similar to the BH3 proteins, Bnip3 has proapoptotic activity which is dependent on the BH3 domain (Yasuda et al., 1998a) . Some of the proapoptotic Bcl-2 family proteins have recently been shown to directly target the mitochondria and to induce apoptotic mitochondrial changes including loss of the membrane potential and release of cytochrome c (Cosulich et al., 1997; Shimizu et al., 1998; Jurgensmeier et al., 1998; Li et al., 1998; Luo et al., 1998; Narita et al., 1998) , leading to apoptosis via activation of death-driving proteases, called caspases (reviewed by Green and Reed, 1998) .
In the present study, we analysed Bnip3L, which we previously identi®ed as a protein showing signi®cant homology with Bnip3 (Matsushima et al., 1998) . We found that Bnip3L possesses the BH3 domain, binds to Bcl-2 and Bcl-x L , exerts pro-apoptotic activity, and directly targets the mitochondria to induce loss of membrane potential and release of cytochrome c.
Results and Discussion

Bnip3L possesses BH3 domain
We have previously described that human Bnip3L shares 56% identity with the amino acid sequences of Bnip3 ( Figure 1a) . We noticed that like Bnip3, Bnip3L possesses a sequence motif similar to the BH3 domain which is conserved in Bcl-2 family of proteins ( Figure  1a and b) . In addition, it also possesses the C-terminal hydrophobic domain which is probably involved in membrane localization (Figure 1a ). To assess any functional role of these domains, we generated two BH3 mutants (Bnip3L-BH3mt and Bnip3L-DBH3) and a mutant (Bnip3L-DC) lacking the C-terminal 32 amino acid residues including the putative membraneanchoring domain (Figure 1c ). The Bnip3L-DBH3 lacked eight amino acid residues of BH3 domain and Bnip3L-BH3mt possessed alanines instead of leucine 134 and aspartic acid 139 . The design for the Bnip3L-BH3mt was based upon the fact that leucine 134 and aspartic acid 139 are well conserved in the BH3 domain of Bcl-2 family proteins and also that they are critical amino acid residues in the BH3 domain of Bak which are required for heterodimerization with Bcl-x L (Sattler et al., 1997) . Another mutant Bnip3L-DBH3/DC was also generated, lacking both the BH3 domain and Cterminal region. All Bnip3L and its mutants were fused at their amino termini with the hemagglutinin epitope (HA).
Bnip3L interacts with Bcl-2 and Bcl-x L
Since Bnip3 has been shown to bind to Bcl-2 (Boyd et al., 1994) , and Bnip3L and Bnip3 reveal a high degree of sequence conservation at the BH3 domain (Matsushima et al., 1998) , we used immunoprecipitation to examine the ability of Bnip3L to interact with anti-apoptotic Bcl-2 protein in mammalian cells. Bnip3L fused at its amino terminal with the HA (HA-Bnip3L) was expressed together with human Bcl-2 by transient co-transfection of COS-7 cells. The cell lysate was ®rst analysed by Western blotting with an anti-HA monoclonal antibody (Figure 2a ). Although the predicted molecular mass of HA-Bnip3L is 25 kDa, HA-Bnip3L protein migrated as two species with molecular masses of 42 kDa and *80 kDa. The same two proteins were seen in stable transfectants expressing HA-Bnip3L and also in the in vitro transcription/translation products (data not shown). It has already been reported that Bnip3 with a predicted molecular mass of 21 kDa is present as a monomer of 30 kDa and dimers of *60 kDa (Chen et al., 1997) . Thus, like Bnip3, Bnip3L seems to eciently form stable dimer of *80 kDa. From the lysate of COS-7 cells that coexpressed HA-Bnip3L and Bcl-2, anti-Bcl-2 antibody co-immunoprecipitated HABnip3L (Figure 2a were substituted by alanine
Pro-apoptotic activity of Bnip3L T Imazu et al between Bnip3L and Bcl-x L was also con®rmed by the yeast two-hybrid system (data not shown). These results indicated that Bnip3L interacts with Bcl-2 and Bcl-x L . Since Bnip3L possesses two notable domains, which are the BH3 and membrane-anchoring domain, we examined the possible requirement of these domains for the interaction with Bcl-2. As shown in Figure 2b , two mutant forms of Bnip3L, BH3mt and DBH3 bound to Bcl-2 to a signi®cantly lesser extent than wild type Bnip3L (WT) did. The deletion of C-terminal region (188 ± 219) including the putative membrane-anchoring domain abolished the interaction of Bnip3L to Bcl-2 ( Figure 2b ). These results indicated that the interaction of Bnip3L with Bcl-2 seems to be dependent upon both the BH3 and the membrane-anchoring domain. As described below, Bnip3L-DC localized primarily in the cytoplasm, whereas Bcl-2 has been shown to be localized in mitochondria, endoplasmic reticulum and nuclear envelope (Monaghan et al., 1992; Akao et al., 1994) , the inability of Bnip3L-DC to bind to Bcl-2 might be due to dierent subcellular localization of these two proteins. Note that Bnip3L-DC existed primarily as a monomer, suggesting that the C-terminal region is required for dimer formation (Figure 2c ).
Mitochondrial localization of Bnip3L
To examine the localization of Bnip3L, Rat-1 cells were transiently transfected with the HA-Bnip3L expression plasmid and were analysed by immuno-¯u orescence microscopy using anti-HA monoclonal antibody ( Figure 3a ) and anti-F 0 F 1 -ATPase (a mitochondrial membrane protein) polyclonal antibody ( Figure 3b ). These two antibodies showed virtually identical staining patterns (Figure 3a and b), which was con®rmed by superimposing the two images ( Figure  3c ). These results indicated that Bnip3L was mainly localized in the mitochondria, the site where most Bcl-2 protein appears to be located (Monaghan et al., 1992; Akao et al., 1994) .
As shown in Figure 3d and e, the BH3mt and DBH3 mutants were localized in the mitochondria as did wild type Bnip3L, whereas Bnip3L-DC was localized mainly in the cytoplasm as judged from the diuse immunostaining ( Figure 3f ) and from the subcellular fractionation experiments in which Bnip3L-DC was recovered in cytoplasmic fractions (data not shown). These results suggested that the C-terminal region including the membrane-anchoring region was required for mitochondrial localization of Bnip3L.
Pro-apoptotic activity of Bnip3L
To assess the biological role of Bnip3L, HA-Bnip3L was transiently expressed in Rat-1 and HeLa cells. Dead cells were assessed as described in Materials and methods, and were more frequently observed after transfection of both cell lines with HA-Bnip3L expression plasmid than with the empty vector (Figure 4a Co-immunoprecipitation of human Bcl-2 and Bnip3L. (a) Plasmids pCAGGS-HA-Bnip3L and pCAGGS (described as HA-Bnip3L in the ®gure) or pCAGGS-HA-Bnip3L and pCAGGS-hBcl-2 (HA-Bnip3L+Bcl-2) were co-transfected into COS-7 cells and cell lysates were immunoprecipitated (IP) using anti-hBcl-2 polyclonal antibody and normal rabbit IgG (NRI) as the control antibody. Each sample was subjected to 9% SDS ± PAGE and Western blot analysis. HA-Bnip3L was detected using anti-HA monoclonal antibody. Strong signals below HA-Bnip3L were due to protein G. (b) Plasmid pCAGGS (vector), pCAGGS-HABnip3L (WT) or pCAGGS-HA-Bnip3L mutants (BH3mt, DBH3, DC or DBH3/DC) were co-transfected with pCAGGS-hBcl-2 into COS-7 cells and cell lysates were immunoprecipitated (IP) using anti-HA polyclonal antibody. Each sample was subjected to 12.5% SDS ± PAGE and Western blot analysis. Bcl-2 was detected using anti-hBcl-2 monoclonal antibody. Part of each precleared lysate (TL) obtained before immunoprecipitation was also loaded to show equivalence with Bcl-2 in the lysates. (c) Part of each precleared lysate (TL) in (b) was subjected to 9% SDS ± PAGE and Western blot analysis using anti-HA monoclonal antibody apoptotic nuclear morphology by Hoechst 33342 staining (data not shown). As shown in Figure 4c , Bnip3L-induced apoptosis was eciently suppressed by Bcl-x L . Similarly, Bcl-2 suppressed Bnip3L-induced apoptosis (data not shown). Bnip3 has previously been shown to exert pro-apoptotic activity (Chen et al., 1997) , so Bnip3L is both structurally and functionally similar to Bnip3. Thus, the growth inhibitory eect of Bnip3L on cancer cell lines which we have previously described (Matsushima et al., 1998) appears to be due to the pro-apoptotic activity of Bnip3L protein.
Pro-apoptotic activity of Bnip3L diminished by BH3 mutations and the deletion of the membrane-anchoring domain
To examine whether the BH3 region and C-terminal region of Bnip3L plays a role in its pro-apoptotic activity, HA-Bnip3L and HA-Bnip3L mutants (BH3mt, DBH3, DC and DBH3/DC) were transiently expressed in Rat-1 and HeLa cells and apoptotic cells were counted. It was seen that Bnip3L-BH3mt and Bnip3L-DBH3 induced less apoptosis than Bnip3L (Figure 5 ), but it was not completely abolished. These results suggested that the BH3 domain played a role in the cell death activity of Bnip3L and that the proapoptotic activity of Bnip3L might also require another domain in addition to BH3. The deletion of the Cterminal region (Bnip3L-DC) completely abolished the pro-apoptotic activity of Bnip3L ( Figure 5 ), suggesting that mitochondrial localization, dimer-formation and binding to anti-apoptotic Bcl-2/Bcl-x L or any combination of these three is required for Bnip3L to exert its pro-apoptotic activity. The similar observations were also reported with Bnip3 (Chen et al., 1997; Yasuda et al., 1998a) . Requirement of the C-terminal region including the membrane-anchoring domain in addition to the BH3 domain in pro-apoptotic activity of Bnip3 and Bnip3L seems to be in contrast to no essential role of the C-terminal region of Bak in its pro-apoptotic activity (Chittenden et al., 1995) .
Mitochondrial membrane potential loss induced by Bnip3L
It was recently reported that BH3-containing proapoptotic members of Bcl-2 family targeted the mitochondria and induced mitochondrial dysfunction including membrane potential loss and release of cytochrome c (Cosulich et al., 1997; Shimizu et al., were incubated with mock protein (Mock), recombinant Bnip3L (WT), or recombinant Bnip3L-BH3mt (BH3mt) at 20 or 50 mg/ml in the presence or absence of recombinant Bcl-x L (20 mg/ml), and Dc was measured using Rh123 after 20 min as described in Materials and methods. (b) Cytochrome c release induced by Bnip3L. Mitochondria (1 mg/ml) were incubated with mock or Bnip3L (20 or 50 mg/ml) in the presence or absence of Bcl-x L (20 mg/ml). After 12 min, samples were centrifuged and aliquots of the supernatants (20 ml each) were subjected to 15% SDS ± PAGE followed by Western blot analysis for cytochrome c (cyt.c). An equal amount of mitochondria was also loaded (Total) 1998; Jurgensmeier et al., 1998; Li et al., 1998; Luo et al., 1998; Narita et al., 1998) . Bnip3L possessed the BH3 domain and was localized in the mitochondria, suggesting that it may target the mitochondria when inducing apoptosis. To test this possibility, isolated rat liver mitochondria were incubated with recombinant HA-Bnip3L or HABnip3L-BH3mt, and the mitochondrial membrane potential was measured with rhodamine 123 (Rh123) as described in Materials and methods. Addition of Bnip3L, but not mock proteins, induced membrane potential loss, and Bnip3L-BH3mt-induced potential loss was greatly reduced at a lower protein concentration (Figure 6a, lanes 1 ± 3) , while the potential was completely abolished by Bnip3L-BH3mt at a higher concentration of 50 mg ( Figure  6a , lanes 4 and 5), consistent with the partial reduction of pro-apoptotic activity of Bnip3L by the BH3 mutations ( Figure 5 ). Recombinant Bcl-x L prevented the membrane potential loss induced by Bnip3L (Figure 6a , lanes 4 and 6). As shown in Figure 6b , Bnip3L was also able to induce release of cytochrome c from isolated mitochondria, and the Bnip3L-induced cytochrome c release was inhibited by recombinant Bcl-x L . These results indicate that Bnip3L has the ability to induce mitochondrial dysfunction via a direct action on the mitochondria. Although it has been reported that C. elegans homologue of Bnip3 (ceBnip3) and human Bnip3 directly interact with caspase(s), possibly inducing the activation of caspases (Yasuda et al., 1998b) , mitochondrial localization of Bnip3L and its requirement for pro-apoptotic activity strongly suggest that Bnip3L plays a dominant role in the mitochondria to exert its pro-apoptotic activity by directly inducing loss of mitochondrial membrane potential and cytochrome c release.
Since BH3 proteins including Bnip3L share limited homology only in the BH3 domain but exert similar eects on the mitochondria, it seems likely that these proteins bind to some mitochondrial receptor when exerting their pro-apoptotic activity. The receptor might be a pro-apoptotic member of the Bcl-2 family like Bak, which may be activated via binding to Bnip3L, or an anti-apoptotic member like Bcl-2, which is inactivated by binding to Bnip3L. Alternatively, Bnip3L might interact with some as yet unidenti®ed non-Bcl-2 family protein in the mitochondria.
It has been reported that pro-apoptotic Bcl-2 family proteins can be activated by several distinct mechanisms, including proteolytic cleavage (Li et al., 1998; Luo et al., 1998) , phosphorylation/dephosphorylation (Zha et al., 1996) , and unidenti®ed modifications leading to translocation and homodimerization in the mitochondria (Gross et al., 1998) . It would be of great interest to determine how Bnip3L is activated during apoptosis, given that it is present as monomers and dimers in the mitochondria and does not appear to be cleaved during cell death (unpublished data).
In conclusion, we showed that Bnip3L, an apoptosis-inducing mitochondrial protein bearing the BH3 domain, directly targets the mitochondria to induce apoptosis-associated mitochondrial changes including membrane potential loss and cytochrome c release.
Materials and methods
Antibodies and chemicals
The anti-HA monoclonal antibody (clone 12CA5) was obtained from Boehringer Mannheim. The anti-HA polyclonal antibody was obtained from MBL (Japan). Antibovine-F 0 F 1 -ATPase rabbit polyclonal antibody was raised in a rabbit immunized with puri®ed bovine heart F 0 F 1 -ATPase, and crossreact with rat F 0 F 1 -ATPase. Anti-Bcl-x polyclonal antibody (S-18) was obtained from Santa Cruz Biotechnology. Anti-hBcl-2 rabbit polyclonal antibody was raised using puri®ed recombinant human Bcl-2. Anti-hBcl-2 hamster monoclonal antibody was obtained from PharMingen. Antipigeon cytochrome c monoclonal antibody (7H8.2C12) which crossreact with rat cytochrome c was kindly provided by Dr E Margoliash (University of Illinois). The other chemicals were obtained from Wako Biochemicals (Osaka, Japan).
Plasmids
The pUC-CAGGS (pCAGGS) expression vector (Niwa et al., 1991) bearing a chicken b-actin promoter and CMV enhancer was used in mammalian cells. The expression plasmid for HA-Bnip3L was constructed so that the nine codons of the HA epitope were fused to the second codon of Bnip3L using PCR primers and pCEP4-Bnip3L (Matsushima et al., 1998) as the template. DNA for HA-Bnip3L-BH3mt (L134A/ D139A), Bnip3L-DBH3, Bnip3L-DC and Bnip3L-DBH3/DC were generated by PCR-based mutagenesis, and inserted into pCAGGS. pCAGGS-hBcl-2 and pCAGGS-hBcl-x L were constructed by inserting the respective human cDNA fragments containing the entire coding region. pGEX-5X-1-HA-Bnip3L, pGEX-5X-1-HA-Bnip3L-BH3mt, and pGEX-2T-hBcl-x L were constructed to produce recombinant proteins by inserting the respective fragments into the pGEX vectors (Amersham Pharmacia Biotech). pEGFP-N1 encoding a green¯uorescence protein (GFP) variant was used for cell death assay as a reporter plasmid (Clontech Laboratories).
Cell culture
The cell lines used were COS-7 (monkey kidney), Rat-1 (rat ®broblast), and HeLa (human uterine cervical cancer). COS-7 cells were cultured in Dulbecco's modi®ed Eagle's medium (DMEM) containing 10% fetal calf serum (FCS) and 0.35% glucose, and Rat-1 cells were cultured in DMEM containing 10% FCS. HeLa cells were cultured in RPMI 1640 containing 10% FCS.
Immunoprecipitation COS-7 cells were co-transfected with plasmid DNAs in the appropriate combinations using LipofectAMINE TM reagent (Gibco BRL). At 24 h after transfection, the cells were collected and were resuspended in lysis buer (10 mM HEPES pH 7.5, 142.5 mM KCl, 5 mM MgCl 2 , 1 mM EGTA, and 0.2% NP40) in the presence of protease inhibitors (0.1 mM p-APMSF, 10 mg/ml aprotinin, 1 mg/ml chymostatin, 1 mg/ml leupeptin, 1 mg/ml antipain and 1 mg/ml pepstatin). After sonication, cell lysates were precleared and immunoprecipitated using speci®c antibodies and control antibodies. Samples were subjected to 12.5% SDS ± PAGE for Bcl-2 or 9% for HA-Bnip3L, and Western blotting was performed. Aliquots of precleared lysates (total lysate: TL) were used to show the equivalent expression and loading of the proteins of interest. 
Immuno¯uorescence staining
Cell death assay
Rat-1 and HeLa cells were transfected with pCAGGS-HABnip3L, pCAGGS-HA-Bnip3L mutants, pCAGGS-hBcl-x L , and empty vector (2.5 mg) in the indicated combinations along with the reporter plasmid pEGFP-N1 (0.5 mg) using LipofectAMINE TM reagent. Cells ( 8610 5 ) were plated into 25 cm 2 tissue culture¯asks (Becton Dickinson) at 18 ± 24 h before transfection. The DNA-LipofectAMINE TM mixture was incubated with the cells for 60 min. At 12 ± 24 h after transfection, the cells were examined using¯uorescence microscopy. GFP-positive cells (100 ± 200 cells) were designated as either live (¯at green cells) or dead (round green cells). Cells were also stained with 10 mM Hoechst 33342 (Calbiochem) for 10 min to assess the nuclear morphology.
Isolation of mitochondria
Mitochondria were isolated from the livers of male Donryu rats as described previously . The mitochondria were resuspended in 0.3 M mannitol, 10 mM potassium HEPES (pH 7.4), and 0.1% fatty acid-free BSA (MT-1 medium).
Protein puri®cation
Bnip3L, Bnip3L-BH3mt, and Bcl-x L were expressed as GSTfusion proteins in Escherichia coli strain DH5a and were puri®ed on a glutathione-Sepharose column. Bnip3L and Bnip3L-BH3mt, and Bcl-x L were released from GST by cleavage with factor Xa and thrombin, respectively. All puri®ed proteins were ®nally suspended in a buer composed of 20 mM Tris-Cl (pH 7.4), 2 mM MgCl 2 , and 1 mM dithiothreitol. Mock control proteins were prepared similarly from empty vectors for GST-tagged proteins.
Measurement of mitochondrial membrane potential
Isolated mitochondria (1 mg protein/ml) were incubated at 258C in MT-1 medium plus 0.5 mM potassium phosphate, 40 mM CaCl 2 , and 4.2 mM succinate to energize the mitochondria. The mitochondrial membrane potential (Dc) was assessed by measuring the Dc-dependent uptake of rhodamine 123 (Rh123) using a spectrophotometer (Hitachi F-4500) with excitation at 505 nm and emission at 534 nm after addition of 10 mM Rh123 to a mitochondrial suspension.
Western blot analysis of cytochrome c release from mitochondria
To detect cytochrome c release from isolated mitochondria, mitochondria incubated with various recombinant proteins were centrifuged, and the supernatants were subjected to Western blot analysis using anti-cytochrome c antibody. Equal amounts of the mitochondrial suspensions were also loaded to show the total cytochrome c level in the mitochondria.
